1H-Pyrrole-1-Heptanoicacid,Beta,Delta-Dihydroxy-2-(4-Fluorophenyl)-5-(1-Methy Calciumsalt(2:1),(R-(R*,R*))-Lethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)

How Crystal Morphology Constrains Direct Compression Feasibility at Commercial Speeds

Direct compression of atorvastatin calcium onto high-output rotary presses operating at 80 000–120 000 tablets per hour forces a confrontation with the active’s intrinsic acicular crystallography. The needle-like habit common to the crystalline trihydrate form—often produced through polymorph-controlled antisolvent crystallization—lends itself to high aspect-ratio particle populations with a median Feret diameter below 25 µm and an interparticulate friction coefficient that readily exceeds 0.8. Without deliberate particle-engineering upstream, the die-filling variance measured gravimetrically across 30-minute campaign samplings on a Fette 3090i can drift beyond 3.5% RSD, triggering out-of-specification uniformity alerts under USP <905> when label claim is as low as 10 mg. Practicable direct compression therefore relies on a co-processed DC-grade premix where the API is pre-blended with fine-particle anhydrous dibasic calcium phosphate (median 10 µm) and a hydrophobic alkalizing stabilizer such as magnesium oxide light at 0.8–1.5% w/w of the total formulation. The calcium salt’s susceptibility to pH-mediated lactonization is suppressed by maintaining microenvironmental pH above 7.0; this strategy is embedded into the pre-mix through dry co-milling in a pin mill equipped with a 0.5 mm screen, achieving a composite particle that simultaneously raises bulk density to 0.55–0.65 g/mL and lowers the Hausner ratio below 1.25. When run on a Korsch XL 400 with an automated weight-control feedback loop, typical compression forces dwell between 8 and 14 kN—exceeding 16 kN has been associated with lamination defects along the equatorial band, a failure mode documented on multiple abbreviated new drug application (ANDA) development reports where insufficient pre-compression dwell left entrapped air in the die bore. The applicable pharmacopoeial framework is the USP Atorvastatin Calcium Tablets monograph, alongside general chapters USP <711> for dissolution (paddle apparatus, 50 rpm, pH 6.8 phosphate buffer with 0.5% sodium dodecyl sulfate) and USP <905> for content uniformity, with residual solvent specification aligned to ICH Q3C Option 2 limits. In a representative 80 mg strength film-coated tablet, the active constitutes 13–16% w/w of the core weight, the remainder being a ternary filler blend of microcrystalline cellulose (PH-102), pregelatinized starch, and lactose monohydrate, with croscarmellose sodium at 2–4% serving as extragranular disintegrant. Equipment-specific process analytical technology (PAT) deployment on the compression suite—typically near-infrared probes monitoring blend uniformity in real time—is cited in FDA science and research reports as a means to clamp the acceptance value of uniformity below 10. The terminal dosage form is the immediate-release atorvastatin calcium tablet commercialised globally as the reference product Lipitor® and available across all major pharmacopoeial regions in strengths of 10, 20, 40, and 80 mg.

Wet granulation in non-aqueous media remains the dominant particle-engineering approach for atorvastatin calcium label claims at 40 mg and above when the cohesive nature of micronized API sourced from a generic manufacture stream precludes robust direct compression at commercial run lengths exceeding 8 hours. The core technological conflict is the molecule’s hydrolytic sensitivity: exposure to liquid water during conventional high-shear granulation provokes rapid C6–C7 lactone ring closure, generating the inert atorvastatin lactone degradant that is restricted to below 0.15% in the USP organic impurities profile. Production-scale processing therefore substitutes anhydrous ethanol or isopropanol as the granulating fluid; a typical binder solution incorporates low-viscosity hydroxypropyl cellulose (Klucel EXF) at 3–6% w/w of the dry powder charge dissolved in ethanol 96% v/v pre-cooled to 8–12°C to reduce solvolytic activity. The granulation endpoint in a GEA Aeromatic-Fielder or Diosna P600 high-shear mixer is determined by impeller power consumption plateauing at 18–22 kW with a chopper speed of 1500 rpm, monitored via torque rheometry; typical wet massing time does not exceed 90 seconds to avoid over-wetting even under inert ethanol-rich conditions. Drying is executed in a Glatt WSG 120 fluid-bed dryer with an inlet air temperature ramped from 35°C to 45°C and dew-point controlled below −10°C, targeting a loss-on-drying endpoint of 0.8–1.2% and residual ethanol below 3000 ppm—half the ICH Q3C Class 3 permitted daily exposure for a 50 kg patient. Granules retained between 20# and 60# mesh sieves are lubricated in a diffusion mixer (Bohle PM 600) with 0.8% w/w magnesium stearate for 3 minutes only; overlubrication beyond 5 minutes increases disintegration time beyond the USP <701> limit of 15 minutes and yields tablets with friability above 0.5%. The manufacturing process is conducted under EU GMP Part II (active substance used as starting material for finished dosage form) and must satisfy the full analytical cascade of ICH Q3D elemental impurities, with particular scrutiny on residual palladium from the Suzuki-type coupling used in the penultimate synthetic step—typically controlled below 10 µg/g through charcoal treatment and recrystallisation before the API enters the granulation suite. Core tablets compressed on a Fette P2200 at 10–15 kN are then film-coated as described in the subsequent segment. The terminal dosage form—an atorvastatin calcium film-coated tablet meeting BP/Ph. Eur./USP monographs—is typically packaged in cold-form aluminium/aluminium blisters when destined for climatic zone IVb territories where ambient humidity exceeds 75% RH during shelf-life conditions stipulated by ICH Q1A stability protocols.

Film Coating Barrier Design for Amorphous Atorvastatin Calcium Core Tablets

While the crystalline trihydrate form offers thermodynamic stability, its surface micro-pitting after compression creates initiation sites for moisture-mediated degradation that require a low-permeability coating envelope. Aqueous ethylcellulose pseudolatex coatings are avoided due to the plasticizer migration into the core’s alkalizing micro-environment; the industry-standard platform instead deploys a fully pre-formulated polyvinyl alcohol (PVA)-based ready-mix system (Opadry® II 85F series) applied at a weight gain of 2.5–3.5% of the core weight. The coating process is run on a side-vented perforated drum coater—IMA Perfima 150 or O’Hara Labcoat III at production scale—with a spray rate of 15–22 g/min per gun using 1.0 mm nozzle tips, atomising air pressure set to 1.5 bar, and pattern air tuned to maintain a 30 cm spray distance from the bed surface. Critical to moisture exclusion is the inlet air dew point: coating efficacy trials compiled in PDA Journal of Pharmaceutical Science and Technology demonstrate that when inlet dew point exceeds +8°C under a 60°C bed temperature, the proportion of atorvastatin lactone formed during the 120-minute coating cycle increases by 0.08–0.12% relative to a dew point of −5°C; operator procedures therefore mandate a desiccant-wheel dehumi-difier upstream of the air handler capable of sustaining −15°C dew point throughout the pan loading. The PVA coat further serves as a taste-masking layer that eliminates the mildly bitter aftertaste detected by electronic-tongue panels when uncoated tablets are placed in pH 5.5 simulated salivary fluid—a sensory attribute cited in patient-compliance studies. Compliance for the film-coating operation draws on USP <1216> (Tablet Friability) and the mechanical integrity tests for coat adhesion: a coated tablet must survive 15 minutes of friability testing (25 rpm) with a coat loss not exceeding 0.2% of the target coat weight. Disintegration testing is carried out per USP <701> in purified water at 37±2°C; the PVA coat is formulated to rupture within 30–60 seconds without impeding the core disintegration that must release at least 80% of the label claim within 45 minutes of dissolution testing under USP <711> using Apparatus II at 75 rpm in a pH 6.8 phosphate buffer containing 0.5% sodium lauryl sulfate. Terminal controlled-atmosphere packaging (cold-form alu-alu blister with a 60 g/m² OPA/Al/PVC laminate) completes the moisture barrier, a configuration that independently validates with a water vapour transmission rate below 0.01 g/(m²·day) at 38°C/90% RH per ASTM F1249. The finished product is the atorvastatin calcium film-coated tablet supplied into institutional and retail pharmacy channels, compliant with EU Falsified Medicines Directive serialisation requirements and stability-committed for 24–36 months in zone II climatic conditions.

When Atorvastatin Calcium Is Combined with Amlodipine Besylate in a Bilayer Tablet

The fixed-dose combination of atorvastatin calcium and amlodipine besylate, originally introduced as Caduet®, introduces compatibility challenges that depart sharply from single-agent tablet engineering because the two pharmacologically synergistic actives occupy radically different pH optima. Amlodipine besylate—a dihydropyridine calcium-channel blocker—is most stable at an acidic microenvironment of pH 3.5–4.5, whereas atorvastatin calcium requires alkaline conditions above pH 7 to suppress lactonisation. Simple wet granulation of a homogeneous blend is therefore contraindicated; the authoritative route adopts a bilayer tablet architecture produced on a specialised Kikusui Aquarius or Fette 4200i bilayer press where each layer is formulated and compressed as an independent granulation charge. The amlodipine layer, constituting 30–35% of the total tablet weight, contains amlodipine besylate equivalent to 5 mg or 10 mg base, microcrystalline cellulose, calcium hydrogen phosphate dihydrate, sodium starch glycolate, and colloidal silicon dioxide, granulated with a purified water-based binder to achieve target particle size 150–250 µm D50. The atorvastatin layer, representing the 65–70% mass remainder, employs the non-aqueous ethanolic granulation protocol detailed earlier, with the additional constraint that the interface polymer—typically a 2–3 mm-thick separating zone of inert, rapidly disintegrating microcrystalline cellulose/kaolin blend—may be pre-compressed at 2–3 kN before the second layer fill station to minimise cross-layer migration of the alkalizer into the amlodipine domain. The final bilayer compaction uses a main compression force of 8–14 kN, and in-process weight control for each layer independently is governed by FDA Guidance for Industry: Fixed Dose Combinations, requiring layer weight RSD values below 2.0% over a 100 000-tablet campaign. Dissolution testing is conducted in two separate media per the individual monographs: amlodipine release is assayed in 0.01 N HCl (USP Apparatus II, 75 rpm), whereas atorvastatin release follows the pH 6.8 method described previously; both layers must exhibit Q = 80% at 45 minutes. The combination product is registered under a New Drug Application or ANDA that demands a full factorial stability program per ICH Q1A(R2), examining the critical degradation pair—amlodipine-related compound A (USP) and atorvastatin lactone—at the 0.5% threshold for identification. In addition, compliance with 21 CFR Part 211 Subpart J requires validated cleaning protocols capable of reducing cross-contamination to below 1 ppm of amlodipine in the atorvastatin layer, verified by LC-MS/MS surface swab recovery studies. The terminal marketing presentation is a bilayer oval tablet imprinted with a dose-specific identifier, supplied in high-density polyethylene bottles with heat-sealed induction seals alongside integrated silica-gel canisters, prescribed for simultaneous management of hypercholesterolemia and hypertension.

Thermal processing of atorvastatin calcium with a polymeric carrier to generate a ternary amorphous solid dispersion (ASD) has been explored as a lifecycle management strategy to address dissolution-rate-limited absorption from the crystalline form in patients with elevated gastric pH following proton-pump inhibitor co-administration. When the crystalline trihydrate is dispersed in a matrix of hydroxypropyl methylcellulose acetate succinate (HPMCAS, AQOAT® AS-LF) at a drug loading of 25–35% w/w, the glass transition temperature of the homogenous dispersion measured by modulated differential scanning calorimetry must exceed 125°C to guarantee physical stability during long-term storage under ICH 40°C/75% RH open-dish conditions. The compounding route employs a co-rotating twin-screw extruder (Leistritz ZSE 18 MAXX) with a barrel profile of 40 L/D, configured with seven independently heated zones where the set temperature is ramped from 110°C in the feed throat to 155–165°C at the mixing zones, while screw speed is maintained between 200–350 rpm to impart sufficient specific mechanical energy (0.15–0.25 kWh/kg) without inducing thermal cleavage of the pyrrole ring. Process analytical technology arrays based on in-line Raman spectroscopy are positioned at the die plate to track the full conversion of crystalline API, as the persistent presence of the 1650 cm⁻¹ amide carbonyl peak indicates undissolved crystallites that would act as nucleation foci during subsequent dissolution. The extrudate strands are quench-cooled on a −15°C chill roll, milled through a FitzMill L1A fitted with a 0.5 mm screen under liquid-nitrogen-chilled conditions, and the resulting powder (D90 < 150 µm) is blended with extragranular crospovidone (5% w/w) and sodium stearyl fumarate (1.2% w/w) prior to compression into immediate-release tablets containing the equivalent of 40 mg atorvastatin. The formulation addition rate—the ASD granulate—represents 55–65% of the total core weight. The applicable regulatory standard for impurity qualification of the extrudate is ICH M7 for potential genotoxic degradation products arising from thermal stress, specifically the monitor of non-volatile pyrrole-condensation dimers at levels not exceeding 25 µg/day. Published data in European Journal of Pharmaceutics and Biopharmaceutics confirm that the ASD-derived tablets, when subjected to dissolution apparatus II in a pH 6.8 biorelevant medium, exhibit a mean dissolution time of 12–18 minutes to 85% release, compared to 45–55 minutes for the crystalline reference, an outcome that re-establishes the robustness of the peroral absorption profile even under hypochlorhydric gastrointestinal conditions. The finished product is a fast-dissolving atorvastatin calcium tablet intended for the ANDA market segment and packaged in desiccant-lined cold-form blisters to preserve the amorphous fraction below the critical recrystallization humidity threshold—published dynamic vapour sorption isotherms indicate that amorphous atorvastatin calcium in HPMCAS matrix remains physically stable as long as headspace relative humidity is kept below 50% at 25°C.